Clinical Trials Browser

Terminated × Interventional × von Hippel-Lindau Disease × Clear all

NCT04895748 2026-03-03

DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

Phase 1 Terminated

CNSEndocrineGenitourinary

Hereditary leiomyomatosis and renal cell cancer, Carcinoma, Renal Cell, von Hippel-Lindau Disease, Paraganglioma, Pheochromocytoma

NCT00330564 2024-06-27

Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow

Phase 2 Terminated

15 enrolled 5 charts

Carcinoma, Renal Cell, Cysts, von Hippel-Lindau Disease, Neoplasms, Hemangioblastoma

NCT03001349 2021-02-15

68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors

Phase EARLY_PHASE1 Terminated

CNSEndocrineNET

von Hippel-Lindau Disease, Meningioma, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1

NCT01266070 2017-02-13

TKI 258 in Von Hippel-Lindau Syndrome (VHL)

Phase 2 Terminated

6 enrolled 5 charts

von Hippel-Lindau Disease, Central Nervous System Neoplasms, Hemangioblastoma

NCT01015300 2012-05-11

Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease

Phase EARLY_PHASE1 Terminated

von Hippel-Lindau Disease, Hemangioblastoma